Selank

Selank Cognitive & Nootropic Overview

Selank is a meticulously engineered neurotrophic compound, designed to heavily bias central nervous activity toward synaptic growth, neuronal protection, and optimized cerebral signaling efficiency.

Physiochemical Profile

Parameter	Value
Molecular Formula	C33H57N11O9
Molecular Mass	751.9 g/mol
Assay Purity	>98.0%
Appearance	Lyophilized solid

Figure 1: Selank Blood-Brain Barrier (BBB) Permeation

Cerebral Mechanism of Action

Detailed cascade of actions triggering its primary nootropic effects:

1. A synthetic analogue of the immunomodulatory peptide Tuftsin.
2. Significantly delays the breakdown of endogenous enkephalins.
3. Normalizes excessive monoamine (Serotonin, Dopamine, Norepinephrine) signaling spikes.
4. Exhibits deep, non-sedating anxiolytic properties within minutes of administration.
5. Upregulates brain-derived neurotrophic factor (BDNF) without the jitteriness of stimulants.

Figure 2: Rate of Synaptogenesis / BDNF Expression

Primary Research Outcomes

• Finding 1: Utilized as a potent generalized anxiety disorder anxiolytic without benzodiazepine withdrawal risks.
• Finding 2: Provides mental ‘smoothing’ and stabilization during intense physiological stress.
• Finding 3: Enhances long-term memory trace consolidation in nervous system trials.

Tuftsin Analogue: Anxiolytic Immunopeptide

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide based on the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro C-terminal sequence that confers protease resistance and blood-brain barrier penetration. Developed alongside Semax at the Institute of Molecular Genetics, Selank uniquely bridges immunomodulation and anxiolytic activity. Its mechanism involves GABAergic modulation, monoamine regulation, and IL-6/enkephalin system interactions that produce anxiety reduction without sedation or dependence.

1. Selank enhances GABA-A receptor sensitivity through allosteric modulation, increasing inhibitory neurotransmission in the amygdala and prefrontal cortex without direct agonism.
2. Serotonin metabolism is stabilized: Selank inhibits the enzymatic degradation of serotonin by modulating MAO-A activity, increasing 5-HT availability in limbic structures.
3. The tuftsin core activates macrophage and NK cell function through tuftsin receptor-mediated signaling, providing immunostimulatory effects alongside anxiolysis.
4. IL-6 expression is modulated bidirectionally—reduced in neuroinflammatory contexts and normalized in immunodeficient states.
5. Enkephalinase inhibition prolongs endogenous enkephalin signaling, contributing to natural anxiolytic and analgesic tone.

Dual Anxiolytic-Immune Research

• Approved Use: Approved in Russia as a 0.15% nasal spray for generalized anxiety disorder (GAD) and neurasthenia, prescribed as a non-benzodiazepine anxiolytic.
• vs. Benzodiazepines: Selank produces anxiolysis comparable to phenazepam (a Russian benzodiazepine) without sedation, cognitive impairment, muscle relaxation, or dependence potential.
• Gene Expression: Microarray studies show Selank modulates 36 genes related to GABAergic neurotransmission, confirming a genomic mechanism underlying its sustained anxiolytic effect.
• Immune Function: The tuftsin-derived immunostimulatory activity makes Selank unique: it reduces anxiety while simultaneously enhancing immune surveillance—important for stress-related immunosuppression research.
• Administration: Intranasal delivery, 2–3 drops per nostril, 3 times daily. Effects onset within 10–15 minutes; therapeutic course typically 14 days. No withdrawal syndrome upon discontinuation.